iZafe Group AB Series B (IZAFE-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, iZafe Group AB Series B (IZAFE-B) has a cash flow conversion efficiency ratio of -0.175x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.89 Million ≈ $-311.01K USD) by net assets (Skr16.49 Million ≈ $1.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
iZafe Group AB Series B - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how iZafe Group AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read iZafe Group AB Series B (IZAFE-B) total liabilities for a breakdown of total debt and financial obligations.
iZafe Group AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iZafe Group AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CONSENSUS AS.MGM.B SK 5-
F:5XI
|
N/A |
|
iRobot Corporation
NASDAQ:IRBT
|
1.770x |
|
HPMT Holdings Bhd
KLSE:5291
|
0.144x |
|
SSR Inc
KQ:275630
|
0.041x |
|
Aberforth Smaller Companies Trust PLC
LSE:ASL
|
0.015x |
|
Georgia Capital PLC
LSE:CGEO
|
0.001x |
|
SSP Group PLC
LSE:SSPG
|
1.962x |
|
Copaur Minerals Inc
V:CPAU
|
-0.008x |
Annual Cash Flow Conversion Efficiency for iZafe Group AB Series B (2012–2024)
The table below shows the annual cash flow conversion efficiency of iZafe Group AB Series B from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is iZafe Group AB Series B worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr9.73 Million ≈ $1.05 Million |
Skr-11.36 Million ≈ $-1.22 Million |
-1.167x | -162.91% |
| 2023-12-31 | Skr25.35 Million ≈ $2.73 Million |
Skr-11.26 Million ≈ $-1.21 Million |
-0.444x | +19.39% |
| 2022-12-31 | Skr38.96 Million ≈ $4.19 Million |
Skr-21.46 Million ≈ $-2.31 Million |
-0.551x | +33.02% |
| 2021-12-31 | Skr40.73 Million ≈ $4.38 Million |
Skr-33.49 Million ≈ $-3.60 Million |
-0.822x | +1.40% |
| 2020-12-31 | Skr29.46 Million ≈ $3.17 Million |
Skr-24.57 Million ≈ $-2.64 Million |
-0.834x | -100.85% |
| 2019-12-31 | Skr36.89 Million ≈ $3.97 Million |
Skr-15.32 Million ≈ $-1.65 Million |
-0.415x | -197.93% |
| 2018-12-31 | Skr10.12 Million ≈ $1.09 Million |
Skr-1.41 Million ≈ $-151.74K |
-0.139x | +58.08% |
| 2017-12-31 | Skr11.19 Million ≈ $1.20 Million |
Skr-3.72 Million ≈ $-400.22K |
-0.332x | +58.28% |
| 2016-12-31 | Skr5.42 Million ≈ $582.96K |
Skr-4.32 Million ≈ $-464.47K |
-0.797x | -292.09% |
| 2015-12-31 | Skr8.72 Million ≈ $938.85K |
Skr-1.77 Million ≈ $-190.78K |
-0.203x | -121.50% |
| 2014-12-31 | Skr9.04 Million ≈ $973.08K |
Skr-829.55K ≈ $-89.27K |
-0.092x | -13.91% |
| 2013-12-31 | Skr11.69 Million ≈ $1.26 Million |
Skr-941.32K ≈ $-101.30K |
-0.081x | +6.07% |
| 2012-12-31 | Skr18.92 Million ≈ $2.04 Million |
Skr-1.62 Million ≈ $-174.55K |
-0.086x | -- |
About iZafe Group AB Series B
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more